The discovery of anticancer drugs is now driven by the numerous molecular alterations
identified in tumor cells over the past decade. To exploit these alterations, it is necessary to …

Medicine will move from a reactive to a proactive discipline over the next decade—a discipline
that is predictive, personalized, preventive and participatory (P4). P4 medicine will be …

The large-scale generation and integration of genomic, proteomic, signalling and metabolomic
data are increasingly allowing the construction of complex networks that provide a new …

Breast cancer patients with the same stage of disease can have markedly different treatment
responses and overall outcome. The strongest predictors for metastases (for example, …

Background A more accurate means of prognostication in breast cancer will improve the
selection of patients for adjuvant systemic therapy. Methods Using microarray analysis to …

The functions of many open reading frames (ORFs) identified in genome-sequencing projects
are unknown. New, whole-genome approaches are required to systematically determine …

Familial cancer syndromes have helped to define the role of tumor suppressor genes in the
development of cancer. The dominantly inherited Li-Fraumeni syndrome (LFS) is of …

Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and
drug responses. To resolve inconsistencies among the reported gene expression–based CRC …

Ascertaining the impact of uncharacterized perturbations on the cell is a fundamental problem
in biology. Here, we describe how a single assay can be used to monitor hundreds of …

The genomes of various tumour cells contain mutant oncogenes that act dominantly, in that
their effects can be observed when they are introduced into non-malignant cells 1–4 . There …